Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 8, 2023

CLINICAL TRIALS PROFILE FOR ENABLEX

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Enablex

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00127270 ↗	Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder	Completed	Procter and Gamble	Phase 4	2005-05-01	This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00127270 ↗	Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder	Completed	Novartis	Phase 4	2005-05-01	This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
NCT00170755 ↗	A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder	Completed	Novartis	Phase 3	2002-04-01	This study will evaluate the safety, tolerability and efficacy of darifenacin, in the long-term treatment of adult patients with overactive bladder.
NCT00170768 ↗	Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over	Completed	Novartis	Phase 2	2005-02-01	The purpose of this study is to explore the possible cognitive effects of darifenacin modified release and long-acting oxybutynin.
NCT00171145 ↗	A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.	Completed	Novartis	Phase 3	2004-04-01	This study will assess the efficacy of a 12-week treatment with darifenacin in increasing warning time, the time from first sensation of urgency to voiding, in patients with OAB.
NCT00171184 ↗	Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder	Completed	Procter and Gamble	Phase 4	2005-04-01	The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Enablex

Condition Name

Chart
Table

Condition Name for Enablex
Intervention	Trials
Overactive Bladder	5
Bioequivalency	2
Healthy	2
Overactive Bladder Syndrome	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Enablex
Intervention	Trials
Urinary Bladder, Overactive	10
Spinal Cord Injuries	1
Urinary Incontinence	1
Urologic Diseases	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Enablex

Trials by Country

Map
Table

Trials by Country for Enablex
Location	Trials
United States	113
Canada	6
Uruguay	2
Chile	1
South Africa	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Enablex
Location	Trials
New Jersey	7
Kansas	5
Florida	5
California	5
Arizona	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Enablex

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Enablex
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	3
Phase 2	1
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Enablex
Clinical Trial Phase	Trials
Completed	12
Unknown status	2
Terminated	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Enablex

Sponsor Name

Chart
Table

Sponsor Name for Enablex
Sponsor	Trials
Novartis	8
Procter and Gamble	5
Laboratorio Elea Phoenix S.A.	2
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Enablex
Sponsor	Trials
Industry	21
Other	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Express Scripts

AstraZeneca

Harvard Business School

McKesson

Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.